Marsha Blackburn (R-TN); Jim Inhofe (R-OK); James Lankford (R-OK); Mike Lee (R-UT); Rand Paul (R-KY); Ben Sasse (R-NE); Tim Scott (R-SC), and Ron Johnson (R-WI).
Also presented without comment: Sasse and Inhofe will run for re-election this fall.
Category: biotech/medical – Page 2,176
Teva donates potential coronavirus treatment to hospitals across the US
This Is-Real!!! Israeli pharmaceutical company, Teva, has announced that they will donate more than 6 million tablets through wholesalers to hospitals across the United States, from March 31.
As the coronavirus is spreading across the world, and the number of people infected is increasing everyday, there is an urgent need to find treatments against COVID-19 that could reduce complications and improve recovery. Recently, the Israeli Health Ministry has approved multiple experiment treatments, and companies worldwide are attempting to determine what could be used to treat COVID-19.
As such, Israeli pharmaceutical company, Teva, has announced that they will donate more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the United States, from March 31. Over 10 million tablets are expected to be shipped within a month.
Teva to send US millions of malaria pills with potential to help COVID-19
Hydroxychloroquine one of several drugs cited in recent days as being possibly effective against coronavirus; Israeli firm says it will provide as many as possible at no cost.
The company said six million doses will be delivered to US hospitals by March 31, and more than ten million in a month.
Israeli generic drug giant Teva announced Friday that it will provide ten million doses of its anti-malarial drug hydroxychloroquine, which could potentially prove effective in fighting the coronavirus pandemic, to US hospitals free of charge. The company said six million doses will be delivered to US hospitals by March 31, and more than ten million in a month. “We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost,” Teva executive vice president Brendan O’Grady said. Get The Times of Israel’s Daily Edition by email and never miss our top stories Free Sign Up.
T-cell-mediated immune response to respiratory coronaviruses
Circa 2014 Emerging respiratory coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) pose potential biological threats to humans. SARS and MERS are manifested as severe atypical pneumonia associated with high morbidity and mortality in humans. The majority of studies carried out in SARS-CoV-infected humans and animals attribute a dysregulated/exuberant innate response as a leading contributor to SARS-CoV-mediated pathology. A decade after the 2002–2003 SARS epidemic, we do not have any approved preventive or therapeutic agents available in case of re-emergence of SARS-CoV or other related viruses. A strong neutralizing antibody response generated against the spike (S) glycoprotein of SARS-CoV is completely protective in the susceptible host. However, neutralizing antibody titers and the memory B cell response are short-lived in SARS-recovered patients and the antibody will target primary homologous strain. Interestingly, the acute phase of SARS in humans is associated with a severe reduction in the number of T cells in the blood. Surprisingly, only a limited number of studies have explored the role of the T cell-mediated adaptive immune response in respiratory coronavirus pathogenesis. In this review, we discuss the role of anti-virus CD4 and CD8 T cells during respiratory coronavirus infections with a special emphasis on emerging coronaviruses.
Coronaviruses belong to the family coronaviridae and are enveloped, positive-sense, single stranded RNA viruses. The coronavirus genome is approximately 31 kb, making these viruses the largest known RNA viruses yet identified. Coronaviruses infect a variety of hosts including humans and several other vertebrates. Coronaviruses are associated with several respiratory and intestinal tract infections. Respiratory coronaviruses have long been recognized as significant pathogens in domestic and companion animals and as the cause of upper respiratory tract infections in humans. Thus, several human coronaviruses (HCoVs) are the etiological agents for mild respiratory illness, including the common cold and croup (e.g.: HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU) (3, 4). Human coronaviruses such as SARS-CoV and MERS-CoV are also associated with severe respiratory illness (5–9).
Drugs from antibodies of Covid-19 survivors
About 80,000 people worldwide have survived a Covid-19 infection. Their immune systems will have produced antibodies, which will help their bodies recognize and fight a repeat attack by the coronavirus. It’s a natural defense mechanism.
Aside from a Covid-19 vaccine, antibodies from recovered patients could provide a short-term “passive immunization” to the disease. A German immunologist saved thousands of lives with the method 100 years ago.